Accustem Sciences OTC Stock Insiders
| ACUT Stock | USD 0.30 0.04 11.76% |
Accustem Sciences employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Accustem Sciences' management performance can provide insight into the firm performance.
| Jeff Fensterer Insider Chief Officer |
| Joe Flanagan Insider Chief Officer |
Accustem |
Accustem Sciences Workforce Comparison
Accustem Sciences is rated third in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 76.0. Accustem Sciences holds roughly 3.0 in number of employees claiming about 4% of stocks in Biotechnology industry.
Accustem Sciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Accustem Sciences Price Series Summation is a cross summation of Accustem Sciences price series and its benchmark/peer.
Accustem Sciences Notable Stakeholders
An Accustem Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Accustem Sciences often face trade-offs trying to please all of them. Accustem Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Accustem Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeff Fensterer | Chief Officer | Profile | |
| Joe Flanagan | Chief Officer | Profile | |
| Wendy Blosser | CEO Director | Profile |
About Accustem Sciences Management Performance
The success or failure of an entity such as Accustem Sciences often depends on how effective the management is. Accustem Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Accustem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Accustem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive HER2- breast cancer and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. Accustem Sciences is traded on OTC Exchange in the United States.
The data published in Accustem Sciences' official financial statements typically reflect Accustem Sciences' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Accustem Sciences' quantitative information. For example, before you start analyzing numbers published by Accustem accountants, it's essential to understand Accustem Sciences' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in Accustem Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Accustem Sciences. Check Accustem Sciences' Beneish M Score to see the likelihood of Accustem Sciences' management manipulating its earnings.
Accustem Sciences Workforce Analysis
Traditionally, organizations such as Accustem Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Accustem Sciences within its industry.Accustem Sciences Manpower Efficiency
Return on Accustem Sciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 |
Additional Tools for Accustem OTC Stock Analysis
When running Accustem Sciences' price analysis, check to measure Accustem Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accustem Sciences is operating at the current time. Most of Accustem Sciences' value examination focuses on studying past and present price action to predict the probability of Accustem Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accustem Sciences' price. Additionally, you may evaluate how the addition of Accustem Sciences to your portfolios can decrease your overall portfolio volatility.